Freeline Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Freeline Therapeutics Holdings's earnings have been declining at an average annual rate of -16.9%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-16.9%
Earnings growth rate
39.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -109.1% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Freeline Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -61 | 39 | 47 |
| 31 Dec 22 | 0 | -89 | 42 | 53 |
| 30 Sep 22 | 0 | -101 | 43 | 66 |
| 30 Jun 22 | 0 | -117 | 41 | 80 |
| 31 Mar 22 | 0 | -132 | 46 | 86 |
| 31 Dec 21 | 0 | -140 | 45 | 93 |
| 30 Sep 21 | 0 | -144 | 49 | 86 |
| 30 Jun 21 | 0 | -138 | 39 | 85 |
| 31 Mar 21 | 0 | -115 | 33 | 70 |
| 31 Dec 20 | 0 | -96 | 26 | 61 |
| 30 Sep 20 | 0 | -73 | 20 | 53 |
| 30 Jun 20 | 0 | -63 | 22 | 40 |
| 31 Mar 20 | 0 | -58 | 17 | 41 |
| 31 Dec 19 | 0 | -54 | 17 | 36 |
| 31 Dec 18 | 0 | -33 | 7 | 26 |
| 30 Sep 17 | 0 | -17 | 7 | 11 |
Quality Earnings: 78F0 is currently unprofitable.
Growing Profit Margin: 78F0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 78F0 is unprofitable, and losses have increased over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare 78F0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 78F0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 78F0 has a negative Return on Equity (-109.09%), as it is currently unprofitable.